The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic responses during the acute phase postburn.
OBJECTIVE
Postburn long-term oxandrolone treatment improves hypermetabolism and body composition. The effects of oxandrolone on clinical outcome, body composition, endocrine system, and inflammation during the acute phase postburn in a large prospective randomized single-center trial have not been studied.


METHODS
Burned children (n = 235) with >40% total body surface area burn were randomized (block randomization 4:1) to receive standard burn care (control, n = 190) or standard burn care plus oxandrolone for at least 7 days (oxandrolone 0.1 mg/kg body weight q.12 hours p.o, n = 45). Clinical parameters, body composition, serum hormones, and cytokine expression profiles were measured throughout acute hospitalization. Statistical analysis was performed by Student t test, or ANOVA followed by Bonferroni correction with significance accepted at P < 0.05.


RESULTS
Demographics and clinical data were similar in both groups. Length of intensive care unit stay was significantly decreased in oxandrolone-treated patients (0.48 +/- 0.02 days/% burn) compared with controls (0.56 +/- 0.02 days/% burn), (P < 0.05). Control patients lost 8 +/- 1% of their lean body mass (LBM), whereas oxandrolone-treated patients had preserved LBM (+9 +/- 4%), P < 0.05. Oxandrolone significantly increased serum prealbumin, total protein, testosterone, and AST/ALT, whereas it significantly decreased alpha2-macroglobulin and complement C3, P < 0.05. Oxandrolone did not adversely affect the endocrine and inflammatory response as we found no significant differences in the hormone panels and cytokine expression profiles.


CONCLUSIONS
In this large prospective, double-blinded, randomized single-center study, oxandrolone shortened length of acute hospital stay, maintained LBM, improved body composition and hepatic protein synthesis while having no adverse effects on the endocrine axis postburn, but was associated with an increase in AST and ALT.
Jeschke
Marc G
MG
Shriners Hospital for Children, and Department of Surgery, University Texas Medical Branch, Galveston, Texas, USA. majeschk@utmb.edu
Finnerty
Celeste C
CC
Suman
Oscar E
OE
Kulp
Gabriela
G
Mlcak
Ronald P
RP
Herndon
David N
DN
D045930:Anabolic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000704:Analysis of Variance; D001823:Body Composition / Q000187:drug effects; D015992:Body Mass Index; D002056:Burns / Q000378:metabolism* / Q000628:therapy; D002153:Calorimetry, Indirect; D016009:Chi-Square Distribution; D002648:Child; D016207:Cytokines / Q000378:metabolism; D004311:Double-Blind Method; D005260:Female; D006728:Hormones / Q000378:metabolism; D006801:Humans; D008297:Male; D008659:Metabolic Diseases / Q000209:etiology / Q000517:prevention & control; D053580:Muscle Strength / Q000187:drug effects; D010074:Oxandrolone / Q000494:pharmacology* / Q000627:therapeutic use; D011446:Prospective Studies; D011506:Proteins / Q000378:metabolism; D018709:Statistics, Nonparametric; D013997:Time Factors; D016896:Treatment Outcome
D045930:Anabolic Agents; D016207:Cytokines; D006728:Hormones; D011506:Proteins; D010074:Oxandrolone
Crit Care Med. 2001 Jul;29(7):1318-24
11445678
J Trauma. 2007 Mar;62(3):676-81
17414346
N Engl J Med. 2001 Oct 25;345(17):1223-9
11680441
J Pediatr Endocrinol Metab. 2002 Feb;15(2):129-38
11874177
Am J Physiol Endocrinol Metab. 2002 Jul;283(1):E172-7
12067858
J Burn Care Rehabil. 2002 Jul-Aug;23(4):288-93; discussion 287
12142585
Ann Surg. 2003 Mar;237(3):422-8
12616128
Lancet Oncol. 2003 Mar;4(3):135
12623350
J Appl Physiol (1985). 2003 Jun;94(6):2273-81
12588788
Minerva Anestesiol. 2003 Apr;69(4):264-74
12766718
J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):267-73
12794565
Ann Surg. 2003 Jun;237(6):801-10; discussion 810-1
12796576
J Trauma. 2004 Jan;56(1):37-44
14749563
J Appl Physiol (1985). 2004 Mar;96(3):1055-62
14578370
Drugs. 2004;64(7):725-50
15025546
Ann Allergy Asthma Immunol. 2004 Mar;92(3):377-8
15049404
Lancet. 2004 Jun 5;363(9424):1895-902
15183630
Steroids. 2004 May;69(5):357-66
15219414
Burns. 2004 Sep;30(6):565-8
15302422
J Clin Endocrinol Metab. 2004 Oct;89(10):4863-72
15472177
Ann Surg. 1974 Oct;180(4):653-69
4412350
Surg Clin North Am. 1978 Dec;58(6):1173-87
32634
J Crit Care. 2000 Mar;15(1):12-7
10757193
Pediatr Nephrol. 2000 Apr;14(4):301-4
10775073
Wound Repair Regen. 2000 Mar-Apr;8(2):97-102
10810035
Ann Med. 2000 Apr;32(3):181-6
10821325
Crit Care Med. 2000 May;28(5):1578-84
10834715
Mayo Clin Proc. 2000 Jan;75 Suppl:S55-9; discussion S59-60
10959218
Ann Surg. 2000 Oct;232(4):455-65
10998644
HIV Hotline. 1998 Dec;8(5-6):2-5
11366381
Ann Surg. 2001 Apr;233(4):556-64
11303139
Br Med Bull. 1985 Jul;41(3):257-64
3896381
Arch Surg. 1990 Mar;125(3):392-5
2306187
Clin Endocrinol (Oxf). 1993 Apr;38(4):393-8
8319371
Arch Surg. 1994 Dec;129(12):1301-4; discussion 1304-5
7986160
J Pediatr. 1995 Feb;126(2):252-6
7844672
JPEN J Parenter Enteral Nutr. 1995 Jul-Aug;19(4):258-65
8523623
Bone. 1995 Nov;17(5):455-60
8579956
J Clin Invest. 1996 Jan 15;97(2):339-48
8567953
Biochem Soc Trans. 1995 Nov;23(4):1019-25
8654673
Horm Res. 1997;48 Suppl 5:83-7
9434050
Shock. 1998 Oct;10(4):298-306
9788663
Ostomy Wound Manage. 1998 Oct;44(10):58-62, 64, 66 passim
9866597
J Clin Endocrinol Metab. 1999 Aug;84(8):2705-11
10443664
Curr Opin Clin Nutr Metab Care. 1999 May;2(3):201-5
10456248
Ann Surg. 2005 Sep;242(3):384-9, discussion 390-1
16135924
J Gerontol A Biol Sci Med Sci. 2005 Dec;60(12):1586-92
16424293
J Burn Care Res. 2006 Mar-Apr;27(2):131-9; discussion 140-1
16566555
J Trauma. 2006 May;60(5):968-71; discussion 971
16688056
Shock. 2006 Jul;26(1):13-9
16783192
Ann Surg. 2006 Jul;244(1):121-30
16794397
Physiol Res. 2006;55(4):421-8
16238457
Shock. 2007 Jan;27(1):4-9
17172973
Pediatrics. 2007 Jan;119(1):e109-16
17130281
Crit Care Med. 2007 Feb;35(2):579-83
17205022
J Appl Physiol (1985). 2001 Sep;91(3):1168-75
11509512